Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

Detalles Bibliográficos
Autores principales: Rule, S, Jurczak, W, Jerkeman, M, Rusconi, C, Trneny, M, Offner, F, Caballero, D, Joao, C, Witzens-Harig, M, Hess, G, Bence-Bruckler, I, Cho, S-G, Thieblemont, C, Zhou, W, Henninger, T, Goldberg, J, Vermeulen, J, Dreyling, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087720/
https://www.ncbi.nlm.nih.gov/pubmed/29572505
http://dx.doi.org/10.1038/s41375-018-0023-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087720/
https://www.ncbi.nlm.nih.gov/pubmed/29572505
http://dx.doi.org/10.1038/s41375-018-0023-2

Ejemplares similares